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Background: Estimating current cancer mortality figures is important for defining priorities for prevention and
treatment.
Materials and methods: Using logarithmic Poisson count data joinpoint models on mortality and population
data from the World Health Organization database, we estimated numbers of deaths and age-standardized rates in
2012 from all cancers and selected cancer sites for the whole European Union (EU) and its six more populated
countries.
Results: Cancer deaths in the EU in 2012 are estimated to be 1 283 101 (717 398 men and 565 703 women)
corresponding to standardized overall cancer death rates of 139/100 000 men and 85/100 000 women. The fall from
2007 was 10% in men and 7% in women. In men, declines are predicted for stomach (220%), leukemias (211%),
lung and prostate (210%) and colorectal (27%) cancers, and for stomach (223%), leukemias (212%), uterus and
colorectum (211%) and breast (29%) in women. Almost stable rates are expected for pancreatic cancer (+2–3%) and
increases for female lung cancer (+7%). Younger women show the greatest falls in breast cancer mortality rates in the
EU (217%), and declines are expected in all individual countries, except Poland.
Conclusion: Apart for lung cancer in women and pancreatic cancer, continuing falls are expected in mortality from
major cancers in the EU.
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introduction
Estimating current cancer mortality figures is important
for defining priorities for prevention, management and
treatment.
Using the World Health Organization (WHO) mortality
database, we estimated the number of deaths and the
corresponding death rates from all cancers and for major
cancer sites for the year 2011 in the European Union (EU) and
in its six more populated countries [1].
The scope of this article is to estimate corresponding
statistics for the year 2012, incorporating the new mortality
data that have been added to the WHO mortality database in
the last year. We also aim to check whether the new data
confirm the trends in mortality rates estimated up to 2011. This
report also focuses on breast cancer mortality data, also
presenting estimated numbers and death rates separately for the
age groups 20–49, 50–69 and 70–79 years.
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materials and methods
This work is an update to the previous work for the year 2011 [1], hence,
methods are similar.
Official death certification data from stomach, intestines (colon and
rectum), pancreas, lung, breast, uterus (cervix and corpus), prostate,
leukemias and total cancer mortality were obtained from the WHO
database (WHOSIS) [2]. Figures were derived for the EU in the period
1970–2007 and up to the most recent available year for six European
countries: France (2007), Germany (2006), Italy (2007), Poland (2008),
Spain (2008) and the UK (2009). The EU was defined as the 27 member
states as of January 2007, i.e. Austria, Belgium, Bulgaria, the Czech
Republic, Cyprus, Denmark, Estonia, Finland, France, Germany, Greece,
Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the
Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden,
UK. Data for Cyprus were not available. For the calculation of the EU rates
only, when data were not available for a country, the nearest available data
(i.e. generally that of the previous or subsequent year) were replicated
(see supplemental Appendix, available at Annals of Oncology online).
In a few countries, mortality data were missing for one or more calendar
years. No interpolation was made for missing data except for the
construction of the EU rates, as described in supplemental Appendix
(available at Annals of Oncology online).
During the calendar period considered, three different Revisions of the
International Classification of Diseases (ICD) were used. Since differences
in classifications between various Revisions were minor, cancer deaths were
recoded for all countries according to the 10th Revision of the ICD [3].
ICD-10 encoding of the studied cancers was stomach cancer (C16),
intestinal (mainly colon and rectum) cancer (C17–C21, C26), pancreas
(C25), lung (C34), breast (C50), uterus (cervix and corpus) (C53–C55,
C58), prostate (C61), leukemias (C91–C95) and total cancers (C00–D48).
Estimates of the resident population, based on official censuses, were
obtained from the same WHO database. Population projection estimates
for the year 2012 were obtained from Eurostat [4].
From the matrices of certified deaths and resident populations, we
computed age-specific rates and numbers of death for each 5-year age
group (from 0–4 to 80+ years) and calendar year. Age-standardized rates,
per 100 000 men and women, at all ages, were computed using the direct
method, on the basis of the world standard population [5]. For breast
cancer quinquennial and annual, standardized mortality rates were also
computed for the 20–49, 50–69 and 70–79 age groups.
A logarithmic Poisson count data joinpoint model was fit to each 5-year
age-specific number of certified deaths in order to identify the most recent
trend segment. The joinpoint model was set to a maximum of five
identifiable segments (four joinpoints) and to have at least five data points
from the last available period [6].
A linear regression was carried out on mortality data from each age
group over the most recent time period identified by the joinpoint model in
order to compute the predicted age-specific certified number of deaths, the
corresponding 95% confidence intervals (CI) and prediction intervals (PI).
Predicted age-specific rates were computed using the predicted population
data from Eurostat and used to compute the predicted standardized death
rates with 95% CI and PI.
results
Table 1 and supplemental Tables S1–S6 (available at Annals of
Oncology online) show total numbers of predicted deaths and
predicted standardized death rates for the analyzed neoplasms
with 95% PI and CI, in the EU as a whole and the six largest EU
member countries in 2012 as well as comparison data from the
last available year.
Figure 1 shows bar-plots of standardized death rates per
100 000 population and certified deaths for the year 2007 and
the predicted rates and number of deaths for 2012 with 95% PIs
for total cancer mortality in the EU in men and women.
Figure 2 shows bar-plots of standardized death rates per
100 000 population for the year 2007 and the predicted rates
for 2012 with 95% PIs for the EU in men and women for the
following cancer sites: stomach, intestine (mainly colon and
rectum), pancreas, lung, female breast, uterus (cervix and
corpus), prostate and leukemias.
Total number of cancer deaths in the EU in 2012 is predicted
to be 1 283 101, of which 717 398 men and 565 703 women, as
compared with 1 261 134, of which 706 619 men and 554 515
women, in 2007. The estimated standardized total cancer death
rates in 2012 are 138.7/100 000 men and 84.7/100 000 women
compared with the 2007 values of 153.5/100 000 men and
90.6/100 000 women. This would correspond to a 10% fall in
men and a 7% fall in women as compared with the most recent
recorded rate. In men, lung cancer accounted for the largest
number of deaths (183 592 deaths, 26% of total male cancer
deaths), with a standardized rate of 37.2/100 000, having fallen
10% from the 41.3/100 000 rate recorded in 2007, based on
183 019 deaths. In women, the favorable total cancer trends are
mainly driven by falls in breast cancer mortality, the first cause
of EU female cancer deaths, making up for 16% of total deaths
with 88 101 deaths and a standardized rate of 14.9/100 000
women (a 10% fall since 2007), colorectal (73 989 deaths,
9.4/100 000 women) and stomach (21 138 deaths, 2.8/100 000
women) cancers. These downward trends in rates are reflected
in all the examined cancer sites with the exception of pancreatic
cancer that had a slight rise in both sexes (39 088 deaths,
8/100 000 men and 38 443 deaths, 5.4/100 000 women) and
female lung cancer that rose from 12.6/100 000 women in
2007 to a predicted rate of 13.4/100 000 (78 658 deaths) for
2012.
Figure 3 shows total cancer death standardized rate trends,
for European men and women, for the central years of
quinquennia (1972–2007) and the predicted rates for 2012.
Figure 4A and B, A (men) and B (women) have the same
structure but show standardized death rates for the examined
specific cancer sites.
Total cancer mortality in the EU is predicted to decline
steadily, as well as rates for male lung cancer, female breast and
colorectal and gastric cancers in both sexes and most other
neoplasms considered. Pancreatic cancer projected a moderate
rise in both sexes, and principally, female lung cancer whose
projected rate (13.4/100 000 women) tended to approach that
of breast cancer (14.9/100 000), were the only exceptions to the
generally favorable trends seen in the EU as a whole.
Supplemental Figure S1 (available at Annals of Oncology
online) illustrates trends in all-ages standardized (world
population) cancer mortality rates for men and women in
quinquennia from 1972 to 2007 and the predicted rates for
2012 for stomach, intestines, pancreas, lung, breast, uterus,
prostate and leukemias in the six studied countries and the EU
as a whole.
Stomach cancer mortality rates were highest in Poland
(11.2/100 000 men and 3.7/100 000 women) and Italy
(7/100 000 men and 3.5/100 000 women) with rates being
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Men Stomach 37424 33926 33267 34585 33467 34384 8.02 6.45 6.31 6.59 6.36 6.54
Intestine (colon
and rectum)
85244 89117 88100 90134 88347 89887 17.68 16.51 16.31 16.72 16.36 16.66
Pancreas 35022 39088 38580 39595 38702 39474 7.86 8.01 7.89 8.14 7.92 8.11
Lung 183019 183592 180850 186334 181383 185801 41.29 37.16 36.51 37.82 36.63 37.69
Prostate 68282 69960 68633 71288 68947 70974 11.97 10.74 10.55 10.92 10.60 10.87
Leukemias 21553 22320 21732 22908 21830 22811 4.81 4.25 4.08 4.42 4.15 4.35
All cancers (malignant
and benign)
706619 717398 710026 724769 711307 723489 153.50 138.70 137.24 140.16 137.60 139.79
Women Stomach 25060 21138 20357 21919 20568 21708 3.65 2.80 2.68 2.91 2.73 2.87
Intestine (colon and
rectum)
75294 73989 73139 74840 73394 74585 10.52 9.37 9.24 9.51 9.29 9.46
Pancreas 34965 38443 37685 39200 37858 39028 5.24 5.38 5.28 5.48 5.30 5.46
Lung 69115 78658 77376 79939 77668 79647 12.61 13.44 13.18 13.70 13.24 13.65
Breast 89012 88101 86693 89508 86978 89223 16.40 14.85 14.58 15.11 14.65 15.04
Uterus (cervix and
corpus)
27393 26720 26191 27249 26291 27148 5.16 4.57 4.45 4.69 4.48 4.67
Leukemias 17884 18605 18224 18987 18337 18873 2.93 2.56 2.47 2.66 2.51 2.62
All cancers (malignant
and benign)





















































2.5- and 4-fold higher than the lowest ones seen in UK males
(3/100 000 men) and 3-fold those in females (1.4/100 000
women). France and Germany also showed rates lower than
those seen in the EU.
Intestinal cancer mortality rates are projected to decline in all
countries considered for women and all countries except
Poland, whose rates however stopped increasing in men.
Colorectal mortality rates in France, Germany and Italy, as well
as British men and Spanish women, are predicted to be
lower than in the EU. Poland had the highest rates again
(20.6/100 000 men and 10.4/100 000 women). The lowest rates
are in Germany (13.9/100 000 men and 7.6/100 000 women).
Pancreatic cancer mortality rates in males varied between
6.6 and 8.2/100 000 men and between 4 and 5.7/100 000
women. Age-standardized rates for this neoplasm were
approximately stable compared with the last recorded data. The
highest rates are in French men (8.2/100 000) and German
women (5.7/100 000), while the lowest ones are in the UK and
Spain in men (6.6 and 6.7/100 000, respectively) and in Spanish
women (4/100 000 women), whose rates are 20% lower than
Figure 1. Bar-plots of standardized death rates per 100 000 population and certified deaths for the year 2007 (dark gray) and the predicted rates and
number of deaths for 2012 with 95% prediction intervals (light gray) for total cancer mortality in the European Union in men and women.
Figure 2. Bar-plots of standardized death rates per 100 000 population for the year 2007 (dark gray) and the predicted rates for 2012 with 95% prediction
intervals (light gray) for the European Union in men and women in the studied cancer sites.
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the second lowest rates seen in British women (5.1/100 000
women).
Male lung cancer rates had favorable trends in all the
studied countries with estimated rates in 2012 varying
between 56.8/100,000 in Poland and 30.1/100,000 in the UK.
Conversely, in women rising trends were observed in all
countries, including the UK, whose female lung cancer rates
had long been high (20/100 000 women), but not been rising
consistently over the past two decades. Consequently, the UK
had the highest rates in women (21.4/100 000 women), over
3-fold higher than the lowest estimated rate for Spain
(6.8/100 000 women).
Estimated female breast cancer mortality rates all resulted in
falling trends. The highest rates were in Germany (16.5/100 000
women) and the lowest ones in Spain (11.7/100 000 women).
Estimated mortality rates for cancer of the uterus in Poland
were three times higher than the lowest ones predicted for
Germany, 7.7 and 2.4/100 000 women, respectively. Remaining
countries and the EU showed values between 3.4 and
4.6/100 000 women. Compared with the last available years,
estimated rates showed favorable changes in all countries.
Prostate cancer estimated mortality rates for 2012 varied
between 8 and 12.8/100 000 men with the highest being in the
UK and Poland, while the lowest ones were in Italy. The trend
for prostate cancer was also favorable in all the studied
countries.
Predicted mortality rates for leukemias for Poland were
higher than for the other countries in both men (5.2/100 000)
and women (2.9/100 000), while for Spain they were lower
(3.3/100 000 men and 1.8/100 000 women). In the remaining
countries and the EU, rates varied between 3.8 and 4.5/100 000
men and 2.2 and 2.7/100 000 women. All the estimated rates
were lower than those recorded in the last available year.
The predicted total cancer standardized mortality trends to
2012 are favorable for all countries considered in both sexes.
The highest estimated rates were in Poland for both sexes,
falling 4% to 185.4/100 000 in men since 2008, and 2% to
102.8/100 000 in women. Total male cancer rates were also
higher than the EU ones in France (145.6/100 000 men, 9% fall
since 2007). Germany, Italy and the UK have predicted male
total cancer mortality rates that are lower than the EU ones,
with Germany and the UK having the lowest ones at 126.9 and
128/100 000 men displaying 9% and 4% falls since 2006 and
2009, respectively. Conversely, total female cancer mortality
rates in the UK are high compared with the EU and the other
studied countries (with the exception of Poland), but they fell
2% since 2009 with a predicted rate of 97.6/100 000 women in
2012. France, Germany and Italy have female rates comparable
to those in the EU (between 78 and 84/100 000 women), while
Spain has sensibly lower female rates, falling 5% and reaching
67.2/100 000 women since 2008.
Table 2 gives standardized breast cancer mortality death
rates in the EU and the six most populous member countries,
for all ages, 20–49, 50–69 and 70–79 years age groups in the
quinquennia 2000–2004 and 2005–2009, with percentage
differences as well as the predicted rates for all the age groups.
Figure 5 shows annual female breast age-standardized death
rates in the EU per 100 000 population for all ages, 20–49,
50–69 and 70–79 years age groups from 1970 to 2007 and the
resulting joinpoint regression model. In addition to the
predicted rates for the year 2012 with 95% PIs.
The projected truncated rates (20–49, 50–69 and 70–79
years) all displayed falling rates in the EU as a whole in 2012
compared with the last available period as well as in most single
countries and age groups, with also a few exceptions: French
70–79 years, German 50–69 years, Spanish 20–49 and 70–79
years and Polish 50–69 and 70–79 years.
discussion
This short-term prediction models estimate that in the year
2012 in the EU 717 000 men and 566 000 women will die of
cancer. These numbers are slightly higher than those recorded
for 2007 (+1.5% in men and +2% in women). The increase in
cancer deaths is due to the aging of the EU population only,
and the age-adjusted cancer mortality rates are expected to
decrease during those 5 years from 153.5/100 000 men in 2007
to 138.7 in 2012 (29.6%) and from 90.6/100 000 women to
84.7 (26.5%). In men, declines are also expected for five of the
six individual cancer sites considered, i.e. stomach (220%),
leukemias (211%), lung and prostate (210%) and colorectal
(27%) cancers. Conversely, a slight increase (+2%) in
pancreatic cancer mortality rates is expected. In women in the
Figure 3. Age-standardized (world population) total cancer mortality
trends in 5-year steps from 1972 to 2007 and the predicted rates for 2012,
for men (squares) and women (circles) in the European Union (EU).
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same 5-year period, mortality rates from five of the seven
individual sites considered are predicted to decline, i.e. stomach
(223%), leukemias (212%), uterus and colorectum (211%)
and breast (29%), while increases in lung (+7%) and
pancreatic (+3%) cancer mortality rates are expected.
The European Code Against Cancer had set a target to
decrease cancer mortality in the EU (at the time composed by
15 member states) by 15% in the 15-year period from 1985 to
2000 [7]. This goal was only partially accomplished since the
actual decrease was 10% in men and 8% in women [8]. In the
year 2000, the mortality rate from all cancers in the EU27 was
169.2/100 000 in men and 97.5 in women. Thus, in 2007, the
all-cancer mortality rates had already declined by over 9% in
men and 7% in women, and the percent decline estimated by
2012 is 18% in men and 13% in women. Thus, the 15% decline
in cancer mortality rates may already have been achieved
after 12 years in men, and appears close for women, in spite
of the unfavorable trends in female lung cancer rates. This is
consistent with the 1.6% per year decline in cancer mortality
(1.8% in men and 1.1% in women) observed in the United
States between 2003 and 2007 [9].
Also within Europe, for all the six countries considered,
declines are more marked in men than women, with however
notable differences. In men, estimated declines in the period
2000–2012 were 21% in France, Germany and Italy, 18% in
Spain, 15% in the UK and 11% in Poland. The UK male
rate, however, was already low, compared with other countries,
due to low gastric and lung cancer rates, and even if the decline
has been somewhat less steep, the 2012 UK rate is still lower
than that of the EU or of the other countries considered, except
for Germany. Conversely, Poland had already the highest
rates in 2000, and thus, the limited subsequent decline will
widen the gap between Poland and the other countries. These
data suggest that the gap in cancer mortality between central
European 2004 accession countries and countries of the EU15
observed in the early 2000s [10] is not projected to decline,
at least in proportional terms, over recent years.
For women, the decline in all-cancer mortality rates in the
period 2000–2012 was estimated to be 15% for Germany,
11%–12% for France, Italy, Spain and the UK and 7% in
Poland. Thus, for women also, the gap between the already
higher rates in Poland and the other countries is likely to
widen.
From the figures presenting trends in mortality rates by
cancer site from 1970 onward for the six countries considered,
some patterns emerge: (i) the steady continuing declines of
stomach cancer mortality rates, reflecting long-term trends in
both period and cohort effects [11]; (ii) the continued tendency
Figure 4. (A) Age-standardized (world population) European Union (EU) male cancer mortality trends in 5-year steps from 1972 to 2007 and the predicted
rates for 2012: stomach (squares), intestines (circles), pancreas (triangles), lung (crosses), prostate (xs) and leukemias (diamonds). (B) Age-standardized
(world population) EU female cancer mortality rate trends in 5-year steps from 1972 to 2007 and the predicted rates for 2012: stomach (squares), intestines
(circles), pancreas (triangles), lung (crosses), breast (xs), uterus (diamonds) and leukemias (inverted triangles).
Annals of Oncology original articles
Volume 23 |No. 4 | April 2012 doi:10.1093/annonc/mds024 | 1049
toward a homogenization of intestinal cancer mortality rates
[12], with the exception of the less favorable trends for Polish
men; (iii) the generalized unfavorable trends in pancreatic
cancer mortality rates, with however, a leveling off in recent
periods, at least in men [13]; (iv) the contrasting trends
between sexes in lung cancer mortality rates, with increases in
women and decreases in men from the 1990s onward, and the
exceptionally high rates in Polish men and women; (v) the early
rises and following marked reductions in breast cancer
mortality rates, larger in the UK, that had higher rates in the
past; (vi) the continuing steady declines in (cervix) uterine
cancers, without, however, evidence of closing the gap between
the higher rates in Poland and the other countries; (vii) the
early rises followed by falls in prostate cancer rates, with again
a less favorable picture for Polish men; (viii) the declines in
leukemia mortality rates, more marked for women and (ix) the
general declines in all-cancer mortality rates in women (since
1980 for the UK), with the exception of Poland, where rates
have been rising up to 2000, and the early increases and
subsequent declines in men, again with a more unfavorable
pattern for Polish men.
Despite declines in breast cancer mortality over most recent
periods in Europe and the Unites States [9, 14, 15], the breast is
still the leading cancer mortality site in women in the EU as
a whole, as well as in France, Germany, Italy and Spain, while
lung cancer is the leading cancer mortality site in the UK and in
Poland. For the year 2012, 88 000 women will die of breast
cancer in the EU, corresponding to almost 16% of all cancer
deaths in EU women, and the estimated rate in the EU is
14.9/100 000 women, 9% lower than the rate observed in 2007.
Predicted breast cancer mortality rates in 2012 are lower in
Spain (11.7) and between 14.5 and 16.5/100 000 in the other
five countries. Spain had the lowest rate in 2000–2004 already
and has also shown a steep decline in the following
quinquennium (29%). The UK had the highest rate in
2000–2004 (20.6), and despite the marked decline in the
following quinquennium (211%), the UK rate was still the
highest in 2005–2009, albeit the gap with the other five
countries was reduced. However, our model predicts that in
2012 the UK rate will be similar—or even slightly lower—than
those of France and Germany.
In relative terms, younger women (20–49 years) are those
who have shown the greatest reductions in rates between
2000–2004 and 2005–2009 (213%) in the EU [15]. In this age
group, Poland shows the most favorable trends (217%)
together with Germany (216%). No declines in rates are
predicted in Polish older women, in contrast to an overall
decline in the EU breast cancer mortality rates of 8% in women
aged 50–69 years and of 6% in women aged 70–79 years.
Consequently, only modest declines have been observed
between 2000 and 2009 and predicted up to 2012 in the Polish
all-age breast cancer mortality rate. However, greater declines
may occur in the future, if the favorable patterns in younger
women will be maintained when these women get older.
The interpretation of the favorable pattern in breast cancer
rates in the EU has raised several controversies, in particular as
concerns the role of mammographic screening. In general,
many important risk factors for breast cancer, including
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obesity, have not changed favorably. This and the spread of
mammographic screening, either spontaneous or organized,
have led to increases in breast cancer incidence rates up to the
early 2000s. Subsequent declines have been attributed, at least
in part, to decreased use of hormone replacement therapy [16].
Important advancements in breast cancer treatment and
management have played a major role in breast cancer
mortality declines, while the role of breast cancer screening is
difficult to quantify [17–19]. It has been pointed out that
declines in breast cancer mortality have started earlier or
simultaneously to the introduction of organized screening
programs in several countries while the effects due to screening
should have started at least a few years later. Moreover, these
reductions have also taken place and been larger in relative
terms, in younger women, while organized screening programs
are mostly directed to women aged 50–69 years.
Obesity is a major risk factor for breast cancer, but only after
the menopause. In an Italian case–control study, the pattern of
risk was consistent with a duration–risk relationship, with
higher relative (and absolute) risks at older ages [20]. The
increases in overweight and obesity observed in several
countries over the last decades [21] have likely unfavorably
influenced breast cancer incidence trends in women >50 years
and more strongly >70 years. Obesity has also been shown to
negatively affect survival after breast cancer in both pre- and
postmenopausal women [22]. While the fraction of breast
Figure 5. Annual female breast age-standardized death rates in the European Union (circles) per 100 000 population for all ages, 20–49, 50–69 and 70–79
years from 1970 to 2007 and joinpoint regression model (full line). With the predicted rates for the year 2012 (dotted line) with 95% prediction intervals.
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cancer deaths attributable to overweight and obesity may not be
negligible in some countries, it is difficult to quantify the
unfavorable role that increases in obesity prevalence has played
on breast cancer mortality rates in different age groups.
As already discussed [1], even short term predictions can be
misleading when an inversion of trends has taken place in
most recent periods that the model is not able to detect. With
one notable exception, the rates estimated for 2012 are in line
with those for 2011 [1], indicating that the new data added to
the WHO database do not indicate that such changes had
occurred.
An exception is lung cancer in women in the UK, where for
2011, we predicted a stable or slightly decreasing rate of 20.3,
while the model predicted a rate of 21.4 in 2012. This reflects
the uncertain trends that lung cancer mortality rates have
shown in UK women. Rates have increased from 13.5 in 1970 to
21.3 in 1988 and subsequently decreased to 19.6 in 2003. While
in the first years of this century (from 2000 to 2005), rates were
19.6–19.9, an abrupt increase took place thereafter with rates
20.5–21 in 2006–2009. Last year, we had the rates up to 2007,
and the model had not picked up the recent increases in trends.
On the other hand, this year predictions appear unduly
influenced by the particularly high rate observed in 2008
(21/100 000), while a lower rate was registered in 2009 (20.5).
In such uncertainty, it is difficult to predict the actual rate in
2012, which may be lower than the one estimated by the model,
i.e. between 20 and 21/100 000 women. It is anyway
discouraging that lung cancer rates in UK women, that are
already among the highest in the EU, do not appreciably
decline over recent years.
Predicted standardized mortality rates may seem inconsistent
with respect to the ones from the previous work [1]; this is
because the model predicts numbers of deaths, while the rates
also depend on the Eurostat population predictions and their
age population structures, and although these may show small
variations between 2011 and 2012, these are unlikely to have an
appreciable effect on rates.
Apart for lung cancer in women and pancreatic cancer, the
fall in mortality from major cancers in major European
countries and the EU essentially reflects the decline in tobacco
smoking in men and the continuing progress in cancer
prevention, early detection and treatment.
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